Andre Lieber
About Andre Lieber
Andre Lieber is a Scientific Co-Founder with extensive training in molecular and applied medicine, specializing in human adenoviruses and innovative cancer treatments.
Andre Lieber Scientific Co-Founder
Andre Lieber holds the position of Scientific Co-Founder at a biotechnology company. His role involves leveraging his extensive expertise in molecular and applied medicine. Throughout his career, Lieber has focused on the biology and translational aspects of human adenoviruses, dedicating nearly three decades to this field. As a scientific co-founder, he has played a pivotal role in developing innovative technologies and validating the safety and efficacy of new therapeutic approaches.
Andre Lieber Expertise in Molecular and Applied Medicine
Andre Lieber's professional background is rooted in molecular and applied medicine. His specialized training allows him to effectively bridge the gap between basic biological research and clinical applications. This expertise has been critical in his work on recombinant adenovirus proteins and in vivo genome engineering of hematopoietic stem cells (HSCs), where he has pioneered new treatments for various diseases.
Andre Lieber Contributions to Adenovirus-Based Cancer Therapy
Andre Lieber has developed groundbreaking approaches for cancer treatment using recombinant adenovirus proteins. His work focuses on designing viruses that can target and treat cancer cells more effectively. These innovative strategies have undergone extensive validation in several murine disease models and non-human primates, showing promising results in terms of safety and efficacy.
Andre Lieber Development of In Vivo Genome Engineering Technology
Andre Lieber has developed a novel technology for in vivo genome engineering of hematopoietic stem cells (HSCs). This approach has shown phenotypic correction in mouse models of Sickle Cell Disease, b-thalassemia, hemophilia A, and spontaneous cancer. Additionally, Lieber's research has demonstrated the potential for genome editing technologies, such as base and prime editors, to treat genetic diseases like Sickle Cell Disease in preclinical models.
Andre Lieber Achievements in Virology and Immunology
Andre Lieber's in vivo research has contributed significantly to virology and immunology. He has utilized adenovirus-based systems to express secreted virus decoy receptors, providing protection against SARS-CoV2 in mice and against Simian/Human Immunodeficiency Virus challenges in rhesus macaques. These achievements highlight the potential of his work to contribute to future therapeutic strategies for viral infections and related diseases.
Andre Lieber Academic Co-Founder of Biotechnology Companies
In addition to his role as a scientific co-founder, Andre Lieber is also an academic co-founder of two other biotech companies: Ensoma Bio and Compliment Corp. These ventures leverage his extensive research experience and innovative approaches to advance the field of biotechnology. His involvement in these companies underscores his commitment to translating academic research into real-world medical solutions.